BIOCORP

Strong Increase in Half-year Results as of June 30th, 2019

Regulatory News:

BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, presents its half-yearly financial results as of June 30^th, 2019.

"After a year 2018 devoted to finalizing products for our customers, major clients in the pharmaceutical industry, BIOCORP has taken a decisive step forward in its development during an extremely rich first half of 2019.
Our ambitious strategy to offer our products and services exclusively B to B has led us to deploy major internal efforts to meet the requirements of the international pharmaceutical players, whether in terms of innovation, quality or regulation. Today, our credibility has been proven. This required from BIOCORP’s team a major investment both timewise and financially. At the end of the first half of 2019, we began to reap the benefits of these efforts.
The first BIOCORP/SANOFI contract clearly shows that our company is now a partner recognized by the most important players in the pharmaceutical industry. The relationship with SANOFI is meant to last and grow. We will pay special attention to this.
In addition, this agreement already guarantees a very satisfactory profitability and therefore contributes greatly to BIOCORP's sustainability.
We are very proud to honor today the promises we made to all our shareholders to transform BIOCORP into a pioneering company in digital health and connected devices, with sustainable and financially profitable business achievements. This change should keep on intensifying in the coming months, thanks to new structuring commercial advances and new product launches that will enable us to address new markets already well identified and further accelerate our growth ", commented Jacques Gardette, President, CEO and founder of BIOCORP.

Highlights of the first half of 2019:

• Strategic partnership with the Israeli group DreaMed Diabetes LTD in order to propose a new solution based on artificial intelligence,
• Partnership with the American company AgaMatrix to co-develop an innovative solution in the field of diabetes,
• CE marking class II-b of the Mallya medical device,

¹ The BIOCORP Board of Directors, meeting on 25 September 2019, approved the accounts for the first half of 2019.